ÂÜÀòÂÒÂ×

As Chairman of Duke Street Bio, Peter draws on his extensive prior healthcare industry experience including advisory, investment and management roles.

He co-founded IOmet Pharma in 2008 where he was CFO, leading financing, business development and commercialisation strategies. Peter led the successful sale of IOmet to Merck/MSD in January 2016.

Before founding IOmet, Peter was a managing director and portfolio manager at Millennium Partners where he ran a global healthcare investment fund; he previously worked at both Morgan Stanley and UBS.